OncoCyte Corp
(FRA:7OC0)
€
3.12
0 (0%)
Market Cap: 22.22 Mil
Enterprise Value: 11.80 Mil
PE Ratio: 0
PB Ratio: 1.83
GF Score: 35/100 - Q1 2024 OncoCyte Corp Earnings Call TranscriptMay 15, 2024Earnings
- Q4 2023 OncoCyte Corp Earnings Call TranscriptApr 12, 2024Earnings
- Q3 2023 OncoCyte Corp Earnings Call TranscriptNov 09, 2023€3.12Earnings
- Q2 2023 OncoCyte Corp Earnings Call TranscriptAug 10, 2023€3.12Earnings
- OncoCyte Corp Extraordinary Shareholders Meeting TranscriptJul 24, 2023
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 23, 2023
- Q1 2023 OncoCyte Corp Earnings Call TranscriptMay 11, 2023€4.8 (+10.09%)Earnings
- Q4 2022 OncoCyte Corp Earnings Call TranscriptApr 03, 2023€5.2 (+11.11%)Earnings
- Q3 2022 OncoCyte Corp Earnings Call TranscriptNov 10, 2022€12 (-2.44%)Earnings
- OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit TranscriptAug 11, 2022
- Q2 2022 OncoCyte Corp Earnings Call TranscriptAug 10, 2022€16.6 (-9.29%)Earnings
- OncoCyte Corp DetermalO™ and Tumor Microenvironment in Clinical Practice Key Opinion Leader TranscriptJun 28, 2022
- Q1 2022 OncoCyte Corp Earnings Call TranscriptMay 11, 2022€21.6 (+4.85%)Earnings
- Q4 2021 OncoCyte Corp Earnings Call TranscriptMar 10, 2022€23.2 (-7.20%)Earnings
- OncoCyte Corp to Discuss Development and Co-Marketing Agreement with Thermo Fisher Scientific Inc Call TranscriptJan 18, 2022
- OncoCyte Corp Investor and Analyst Day TranscriptDec 14, 2021
- Q3 2021 OncoCyte Corp Earnings Call TranscriptNov 09, 2021€60 (+4.90%)Earnings
- OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer TranscriptSep 28, 2021
- OncoCyte Corp Key Opinion Leader Presentation Part 1: Transplant Rejection Testing TranscriptSep 22, 2021
- Q2 2021 OncoCyte Corp Earnings Call TranscriptAug 10, 2021€83.6 (+0.48%)Earnings
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 24, 2021
- Q1 2021 OncoCyte Corp Earnings Call TranscriptMay 17, 2021€63.6Earnings
- OncoCyte Corp DetermaIO™ Data KOL Webinar TranscriptApr 19, 2021
- Q4 2020 OncoCyte Corp Earnings Call TranscriptMar 16, 2021€82.4 (+4.04%)Earnings
- Q3 2020 OncoCyte Corp Earnings Call TranscriptNov 12, 2020€29.8 (+4.93%)Earnings
- OncoCyte Corp - EGFR And Molecular Risk Stratification In Early-Stage NSCLC TranscriptOct 22, 2020
- OncoCyte Corporation - Special Call TranscriptAug 19, 2020
- Q2 2020 OncoCyte Corp Earnings Call TranscriptJul 29, 2020€23.6 (+1.72%)Earnings
- OncoCyte Corp Announces Completion Of Determadx™ Clinical Validation Study TranscriptJun 29, 2020
- OncoCyte Corp Annual Shareholders Meeting TranscriptJun 17, 2020
- Q1 2020 OncoCyte Corp Earnings Call TranscriptMay 12, 2020€52.4 (+0.77%)Earnings
- Q4 2019 OncoCyte Corp Earnings Call TranscriptMar 25, 2020€37 (+1.65%)Earnings
- OncoCyte Corp to Acquire Insight Genetics Inc - Conference Call TranscriptJan 10, 2020
- Q3 2019 OncoCyte Corp Earnings Call TranscriptNov 14, 2019€29 (-3.97%)Earnings
- Q2 2019 OncoCyte Corp Earnings Call TranscriptAug 14, 2019€36.92 (+5.23%)Earnings
OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 11, 2022 / 09:00PM GMT
Release Date Price:
€18.3
(+10.24%)
Elizabeth Cristina Mari Garcia
UBS Investment Bank, Research Division - US Life Science Analyst
All right. Hello. Welcome, everybody. You've got me back, Liza Garcia, UBS Life Science Tools & Diagnostics Analyst. And I am very, very fortunate as I am joined here by the CEO of OncoCyte. And he will be diving into some fireside chat questions. So thank you very much for joining me.
Ronald A. Andrews
OncoCyte Corporation - President, CEO & Director
Thanks for having me.
Questions & Answers
Elizabeth Cristina Mari Garcia;Ronald A. Andrews
UBS Investment Bank, Research Division - US Life Science Analyst;OncoCyte Corporation -
Great. Awesome. So I was thinking maybe we'll start off with the portfolio and kind of walk through it and kind of get a lay of the land for people who may not be as familiar with the OncoCyte story. So let's start off with DetermaRx, the lung cancer stratification test. Could you maybe walk us through the use case here? Let's start there.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)